We invest in great companies at a time when they are still very small

2008

19 December 2008
IDEA AG completes recruitment in two clinical studies with Diractin® (ketoprofen in Transfersome® gel), including the biggest German biotech study to date

17 November 2008
InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery

14 November 2008
Hodogaya promotes its transport materials for the Novaled PIN OLED™ structures

11 November 2008
IMM, Cenix and Alnylam discover new targets in Malaria Infection with RNAi Technology

5 November 2008
IDEA AG reports data of a 12-month comparative study of the targeted analgesic Diractin® (ketoprofen in Transfersome® gel) versus naproxen and gives development update

28 October 2008
Novaled is Germany's fastest growing mid size company

20 August 2008
Novaled achieves break through in organic CMOS-type technology

24 July 2008
Santhera erhält erste Marktzulassung: Catena® erhält Zulassung von Health Canada zur Behandlung von Friedreich-Ataxie

28 May 2008
CDT, Sumitomo Chemical and Novaled will collaborate to evaluate Novaled PIN OLED™ structures in Polymer OLEC devices.

20 March 2008
Cenix BioScience and CellCentric sign Framework Research Agreement for RNAi-Based Target Validation

19 March 2008
Cenix BioScience signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery

10 January 2008
Saint-Gobain and Novaled have demonstrated the feasibility of large area OLEDs



Homepage Erstellung und Pflege: Superweb Homepage-Erstellung Version 1.0